EDAP TMS S.A. ((EDAP)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EDAP TMS S.A. struck an upbeat tone on its latest earnings call, highlighting powerful commercial momentum for its Focal One robotic HIFU platform despite deeper losses. Management underscored record revenue, expanding clinical validation and international traction, while acknowledging higher expenses, cash usage and inventory build as the cost of funding rapid growth.
Record Quarterly Revenue on Strong HIFU Demand
EDAP reported Q1 2026 revenue of $17.8 million, a 25% jump from $14.3 million a year earlier, as its HIFU franchise continued to scale. The top-line performance set a new quarterly record, underscoring how the company’s focused strategy around Focal One is reshaping its revenue mix.
HIFU Revenue Nearly Doubles on Capital and Treatment Growth
Total HIFU revenue surged to $11.6 million from $6.5 million, marking a 78% year-over-year increase driven by both system sales and recurring usage. Eleven capital sales, up from six, combined with a 30% rise in treatment-driven revenue to show Focal One gaining traction as both a product and a procedure platform.
U.S. Procedure Volumes Highlight Growing Clinical Adoption
U.S. Focal One procedure volumes climbed 53% year-over-year, fueled by expanded physician training and higher utilization at existing centers. This surge in clinical activity signals deeper integration of HIFU into everyday practice and points to a growing base of recurring revenue from procedures.
Gross Margin Expansion Despite Growth Investments
Gross profit increased to $8.1 million from $6.0 million, lifting gross margin to 45.7% versus 42.0% a year ago. HIFU-specific gross margin also improved to 51.4% from 48.6%, suggesting better scale economics even as the company pushes aggressively into new markets.
System Placements Accelerate Across U.S. and Overseas
EDAP completed 11 capital sales and 10 net system placements in the quarter, marking a broad-based commercial expansion. Notable moves included a UPMC cash conversion, installs at Moffitt Cancer Center and Mass General Brigham, plus first deliveries and cash sales in Mexico, France, Hungary and Cleveland Clinic London.
HIFI-2 Study Strengthens Salvage HIFU Case
The company spotlighted publication of HIFI-2, the largest prospective salvage study with more than 500 patients, as a key clinical milestone. Data showing high rates of avoidance of hormone deprivation therapy bolster the case for salvage HIFU and support reimbursement and guideline alignment.
Multi-Indication Strategy Builds Beyond Prostate Cancer
Management emphasized demand for Focal One in both prostate cancer and deep infiltrating endometriosis, underscoring its multi-indication strategy. Active endometriosis rollouts in Europe, a packed symposium with more than 400 participants and ongoing BPH studies with Mount Sinai point to additional growth avenues.
Balance Sheet Bolstered Amid U.S. Regulatory Shift
EDAP noted it became a U.S. domestic issuer as of January 1, 2026 and will now report in dollars, marking a key corporate transition. Liquidity received a boost after quarter end with roughly $14 million from a European Investment Bank credit facility, providing added support for ongoing investments.
Noncore Segments Weigh on Overall Mix
While HIFU surged, noncore distribution and ESWL businesses saw revenue drop 20% year-over-year, partially offsetting gains. The weaker performance in these legacy areas reinforces the company’s pivot toward HIFU as its primary growth and value driver.
Operating Expenses Rise and Losses Deepen
Operating expenses climbed to $15.5 million from $12.3 million, reflecting higher sales spending and costs tied to the U.S. issuer transition. As a result, operating loss widened to $7.4 million from $6.3 million, highlighting the near-term profitability trade-off of funding expansion.
Net Loss Impacted by Non-Cash Charges
Net loss increased to $9.1 million, or $0.24 per share, versus $7.4 million, or $0.20 per share, in the prior year’s quarter. The deeper loss reflected the higher operating deficit and a $1.7 million non-cash charge related to warrants and interest, partially offset by favorable currency effects.
Cash Usage and Inventory Build Reflect Growth Push
Cash and equivalents fell to $15.0 million from $20.5 million at year-end, as operating cash supported HIFU expansion before the subsequent EIB funding. Inventory ticked up to $13.3 million from $12.8 million, with management framing the build as necessary to meet rising demand for systems.
External Headwinds Add to Near-Term Pressure
The company cited roughly $400,000 of tariff impact on the quarter’s profit and loss statement, adding an external drag on results. Combined with the earlier mentioned non-cash warrant and interest charge, these factors amplified reported losses despite strong underlying growth.
Guidance Reaffirmed on Strength of HIFU Growth
EDAP reaffirmed full-year 2026 guidance calling for core HIFU revenue between $50 million and $54 million, implying 34% to 45% growth over 2025, and noncore revenue of $22 million to $26 million. Management pointed to Q1’s 25% total revenue growth, 78% HIFU growth and higher margins as evidence that the business remains on track even as costs and tariffs pressure near-term earnings.
EDAP’s latest call portrayed a company trading short-term margin and cash comfort for long-term scale in robotic HIFU. For investors, the story hinges on whether record HIFU growth, stronger clinical validation and expanding global placements can eventually outpace rising expenses and noncore declines to deliver sustainable profitability.